Attitudes toward clinical trials across the Alzheimer's disease spectrum.

ABSTRACT:

Background

Research has revealed that manifest Alzheimer's disease (AD) dementia is preceded by preclinical and prodromal phases during which pathology is accumulating but function remains intact. This understanding and concern that disease-modifying interventions initiated at the dementia stage may come too late in the neurodegenerative process to be successful has led to a paradigm shift in AD clinical trials. AD trials now enroll patients with mild cognitive impairment (MCI) and persons with no cognitive symptoms. Trial designs are similar to those enrolling dementia participants. We set out to test the hypothesis that attitudes towards trial design features differ among different potential AD trial populations.

Methods

We sent a survey composed of 37 items assessing spec

SUBMITTER: Nuno MM 

PROVIDER: S-EPMC5628443 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature